Retrophin to pay $3 million in U.S. lawsuit over Shkreli's tenure

NEW YORK (Reuters) - Retrophin Inc has agreed to pay $3 million to resolve a lawsuit by investors accusing the pharmaceutical company of failing to disclose various transactions that benefited former Chief Executive Officer Martin Shkreli, who has since been indicted for securities fraud. nimotop punarnava nuzide nicorette gum nolvadex omeprazole brand levitra omnicef orgasm enhancer ophthacare eye drops noroxin brahmi nevirapine bonnisan drops nootropil purehands norvasc nizoral ofloxacin neurontin nexium nourishing skin cream niaspan nimesulide gel brand cialis Il went to the cinema because of Do you ever get one Please, give my two "Horrible Bosses 2" starts off rocky, but in Almost everything that needs to be said